Mylan has a vast manufacturing platform in India, making it the third largest pharmaceutical exporter in the country. The platform comprises nine active pharmaceutical ingredient (API), eight oral solid dose (OSD) and eight injectables manufacturing units that serve a number of markets around the world and produce medicines in a wide range of therapeutic areas.
Sixteen of Mylan’s facilities in India, including eight of its API facilities, are approved by the U.S. Food and Drug Administration (FDA). Many of the sites also are approved and regularly inspected by other regulatory authorities, including Australia's Therapeutic Goods Administration, the U.K.’s Medicines and Healthcare Products Regulatory Agency and the World Health Organization.
Mylan’s globally integrated R&D platform is expanding our product portfolio to satisfy unmet medical needs. We have more than 2,900 R&D and regulatory experts who work collaboratively across 10 different centers around the world. About half of our scientific affairs workforce is based in India working at our global R&D center of excellence in Hyderabad, our injectables R&D center in Bangalore or our OSD R&D center in Ahmedabad.